Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base (HIT-1)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2010 by Heidelberg University
Sponsor:
Information provided by:
Heidelberg University
ClinicalTrials.gov Identifier:
NCT01182779
First received: July 26, 2010
Last updated: August 16, 2010
Last verified: July 2010

July 26, 2010
August 16, 2010
July 2010
August 2015   (final data collection date for primary outcome measure)
local-progression free survival (LPFS) [ Time Frame: 8-years ] [ Designated as safety issue: No ]
The primary objective of this study is to evaluate, if the innovative therapy (carbon ion irradiation) in chordomas is superior to the standard proton treatment with respect to the LPFS defined as time from the randomisation to observed local reccurrence or death from any cause in the absence of documented local disease progression. Lo-cal recurrence defined as MRT or CT - morphological tumor progress in the former irradiated region. A 10% increase in the LPFS is considered clinically relevant as-suming that the LPFS rate for the proton therapy is 70%.
Same as current
Complete list of historical versions of study NCT01182779 on ClinicalTrials.gov Archive Site
  • Survival [ Time Frame: 8-years ] [ Designated as safety issue: No ]
    Assessment of overall survival, progression free and metastasis free survival.
  • Local control and patterns of recurrence [ Time Frame: 8 years ] [ Designated as safety issue: No ]
    Local recurrences will be confirmed radiologically and histologically whenever possible. At least two medical doctors (radiation oncologist and/or radiologist) will be required to judge of the recurrence.
  • Toxicity [ Time Frame: 8 years ] [ Designated as safety issue: No ]
    Acute and late toxicity will be analysed due to Common Terminology Criteria for Adverse Events: CTCAE V4.0 for acute reaction and RTOG/EORTC for late effects.
Same as current
Not Provided
Not Provided
 
Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base
Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base -Clinical Phase III Study-

This study is a prospective randomised clinical phase III trial. The primary objective of this study is to evaluate, if the innovative therapy (carbon ion irradiation) in chordomas is superior to the standard proton treatment with respect to the local-progression free survival (LPFS).

The study is a prospective randomised clinical phase III trial. The trial will be carried out at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial.

Proton therapy is the gold standard in the treatment of skull base chordomas. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed.

Patients with skull base chordoma will be randomised to either proton or carbon ion radiation therapy. As a standard, patients will undergo non-invasive, rigid immobilization and target volume delineation will be carried out based on CT and MRI data. The biologically isoeffective target dose to the PTV in carbon ion treatment (accelerated dose) will be 63 Gy E ± 5% and 72 Gy E ± 5% (standard dose) in proton therapy respectively. Local-progression free survival (LPFS) will be analysed as primary end point. Toxicity and survival are the secondary end points. Also matters of interest are patterns of recurrence, prognostic factors and plan quality.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Chordoma
  • Tumor
  • Treatment
  • Radiation: Carbon ion

    Arm A (carbon ion therapy):

    Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E.

  • Radiation: Protons

    Arm B (proton therapy):

    Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E.

  • Experimental: A

    Arm A (carbon ion therapy):

    Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E.

    Intervention: Radiation: Carbon ion
  • Active Comparator: B

    Arm B (proton therapy):

    Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E.

    Intervention: Radiation: Protons

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
319
August 2023
August 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Karnofsky Performance Score ≥60%
  • Age >18 years and <80 years
  • Informed consent signed by the patient
  • Histological confirmation of chordoma with infiltration of the skull base.

Exclusion Criteria:

  • Inability to understand the aims of the study, no informed consent
  • Prior RT of skull base region
  • Other malignancies with disease-free interval < 5 years (excepting pre- cancerous lesions)
  • Participation in another trial
  • Pregnancy
  • Simultaneous CHT or Immunotherapy.
Both
18 Years to 80 Years
No
Contact: Anna V. Nikoghosyan, MD +496221568202 anna.nikoghosyan@med.uni-heidelberg.de
Contact: Juergen Debus, MD, PhD +496221568202 juergen.debus@med.uni-heidelberg.de
Germany
 
NCT01182779
HIT-1
Yes
Juergen Debus, MD PhD, Dept. of Radiation Oncology, INF 400, 69120 Heidelberg, University of Heidelberg
Heidelberg University
Not Provided
Principal Investigator: Juergen Debus, MD PhD Heidelberg University
Heidelberg University
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP